Moderna’s mRNA Flu Vaccine Moves Closer to U.S. Approval

Imagine redesigning a seasonal vaccine in weeks instead of months. That possibility is what has pushed Moderna’s first mRNA influenza shot, mFlusiva, into the spotlight as regulators weigh whether to let it into American clinics.

This week an independent advisory committee to the U.S. Food and Drug Administration voted unanimously that the vaccine’s benefits outweigh its risks for older adults, a major procedural step that now lands on the FDA’s desk as it prepares a final decision.

Moderna has applied for full approval for people aged 50 to 64, and simultaneously requested authorization for those 65 and older so it can continue collecting data while the vaccine is used. The approach is pragmatic: move the product toward patients who stand to gain most, while completing larger trials in the oldest age group.

Evidence is beginning to stack up. In a trial of roughly 40,000 participants aged 50 and up, mFlusiva reduced laboratory-confirmed influenza cases by about 27% compared with a commonly used flu vaccine. A smaller study among people 65 and older found that Moderna’s shot produced a stronger immune response than the current high-dose vaccine recommended for seniors.

Side effects were notable but expected: sore arm, fever, headache, fatigue and muscle aches were reported more often than with some existing flu shots, though generally transient. The FDA characterized this reactogenicity as consistent with what is seen from mRNA platforms.

"Our ability to update mRNA vaccines rapidly allows us to match the latest circulating strains and could prevent thousands of hospitalizations among older Americans," Dr. Ritubarna Das of Moderna told FDA advisers during the briefing, underscoring the speed advantage that made mRNA pivotal in the COVID-19 response.

Speed matters because influenza is a moving target. When the seasonal vaccine mismatches the dominant circulating strain, severe cases and hospitalizations rise. mRNA’s shorter production timeline narrows that window of mismatch, potentially reducing the risk that a shot becomes obsolete before the season peaks.

FDA reviewer Timothy Brennan noted the agency still wants more data on frail elders and immunocompromised people, but signaled a desire to have an additional tool available before the next flu season. If approved, Moderna plans a massive follow-up study of about 400,000 people aged 65 and older: half would receive the mRNA vaccine and half a current high-dose vaccine, with the trial repeated over two flu seasons to capture real-world performance.

Whether mRNA will become the new standard for seasonal influenza is now a question of regulatory scrutiny, large-scale data and timing. Either way, the industry is watching closely as a technology that rewrote the pandemic playbook edges toward rewriting the flu playbook—and perhaps the next winter's casualty statistics along with it.